BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI) announced today thatChaim Lebovits, CEO and President, will provide an update of the Company's ALS and MS trials and company growth strategy at The BIO CEO & Investor Conference, being held February 10-11, 2020at the New York Marriott Marquis.
Brainstorm has a fully enrolled 200-patient Phase 3 clinical trial (NCT03280056) evaluating repeat intrathecal administration of NurOwn® cellular therapeutic (autologous MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). In lateOctober 2019, the Data and Safety Monitoring Board (DSMB) completed the second planned interim safety analysis for the first 106 patients who received repeat dosing of NurOwn in the Phase 3 ALS trial.
Additionally, Brainstorm is enrolling participants in the Phase 2 study of repeat intrathecal administration of NurOwn for progressive MS, a disease with significant unmet medical need.
Presentation and Webcast Details:
Presenter: Chaim Lebovits, CEO, BrainStorm Cell Therapeutics, NYC, NY.
Date: Tuesday, February 11, 2020
Time: 10:30 am Eastern Time
Webcast Link: https://bit.ly/31r0nJd